JP2016504109A - 乾燥粉末吸入器および使用方法 - Google Patents
乾燥粉末吸入器および使用方法 Download PDFInfo
- Publication number
- JP2016504109A JP2016504109A JP2015549353A JP2015549353A JP2016504109A JP 2016504109 A JP2016504109 A JP 2016504109A JP 2015549353 A JP2015549353 A JP 2015549353A JP 2015549353 A JP2015549353 A JP 2015549353A JP 2016504109 A JP2016504109 A JP 2016504109A
- Authority
- JP
- Japan
- Prior art keywords
- dose
- acetylsalicylic acid
- aspirin
- less
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
心筋梗塞、深部静脈血栓症、肺血栓塞栓症、血栓性脳卒中等のような血栓塞栓症は、かかる血栓塞栓症のための初期療法または治療を提供することを可能にする或る症状とともに表れることがある。いくつかの状況では、81mgの低用量すなわちベビーアスピリン、または、標準アスピリン(330mg)が、患者の初期治療を提供するために経口投与されるのがよい。
薬剤は、異なる仕方、例えば、液体、カプセル、タブレット、または、噛むことができるタブレットで、経口的に投与することができる。経口ルートは、最も便利であり、最も安全であり、かつ、最も費用が安いので、最もしばしば使用される。しかしながら、経口薬剤送達は、薬剤が消化管を通って典型的に移動する仕方のために、制限を有する。
アスピリンは、サリチル酸のアセチル化形態であり、アスピリン中の活性化学は、アセチルサリチル酸(ASA)と呼ばれる。アスピリンは、望ましい効果を達成するために、数百万の人々によって使用されており、多くの人々によって、ベビーアスピリンが、しばしば毎日使用されている。アスピリンの主要な効果は、シクロオキシグナーゼ酵素(特に、COX1(シクロオキシナーゼ-1)およびCOX2(シクロオキシナーゼ-2)酵素)の機能を害することである。
上述したように、アスピリンの経口送達は、痛みおよび消化不良を生じさせる胃への損傷の危険、並びに、出血の高い危険を生じさせることがある。さらに、本願に開示されている実施形態の観点の少なくとも1つによれば、血栓塞栓症を引き起こすことがある緊急事態中薬剤を経口投与することはしばしば困難であるという理解がある。例えば、患者は、吐き気を経験し、或いはその他の仕方で、薬剤を経口的に摂取することができないことがある。さらに、薬剤の経口投与は、薬剤が血流に直ちに到達せず、かくして、薬剤の重要な効果を遅延させるので、望ましくないことがある。肝臓および腸におけるファーストパス作用により、系の循環に到達する薬剤の量は、投与された量よりもはるかに少なくなる。したがって、本願に開示されている種々の実施形態の観点によれば、代替的投与ルートが、この望ましくない副作用を回避できるであろうという理解がある。
Claims (15)
- 血栓塞栓症の危険を減少させるための方法であって、該方法は、乾燥粉末吸入器によって、患者の血栓塞栓症の危険を減少させるのに効果的なアセチルサリチル酸の用量を投与し、前記乾燥粉末吸入器は、マウスピースと、アセチルサリチル酸の用量を受け入れるためのリザーバと、患者によってマウスピースを通して吸収されるためのアセチルサリチル酸の用量を利用可能にする作動部材と、を有し、前記アセチルサリチル酸の用量の量は、約30mgよりも少ないアセチルサリチル酸である、方法。
- 前記用量は、25mgよりも少ない量である、請求項1に記載の方法。
- 前記用量は、20mgよりも少ない量である、請求項1に記載の方法。
- 前記用量は、15mgよりも少ない量である、請求項1に記載の方法。
- 前記用量は、10mgよりも少ない量である、請求項1に記載の方法。
- 前記用量は、5mgよりも少ない量である、請求項1に記載の方法。
- 前記用量は、2mgよりも少ない量である、請求項1に記載の方法。
- 前記用量は、血栓塞栓症の症状に応じて予備治療として投与される、請求項1に記載の方法。
- 血栓塞栓症の危険を減少させるための薬剤送達システムであって、該システムは、
血栓塞栓症の危険を減少させるのに効果的な粉末形態のアセチルサリチル酸の用量と、
乾燥粉末吸入器と、を含み、前記乾燥粉末吸入器は、マウスピースと、アセチルサリチル酸の用量を受け入れるためのリザーバと、患者によってマウスピースを通して吸入されるためのアセチルサリチル酸の用量を利用可能にする作動部材と、を有し、
前記アセチルサリチル酸の用量の量は、約30mgよりも少ないアセチルサリチル酸である、システム。 - 前記用量は、25mgよりも少ない量である、請求項9に記載のシステム。
- 前記用量は、20mgよりも少ない量である、請求項9に記載のシステム。
- 前記用量は、15mgよりも少ない量である、請求項9に記載のシステム。
- 前記用量は、10mgよりも少ない量である、請求項9に記載のシステム。
- 前記用量は、5mgよりも少ない量である、請求項9に記載のシステム。
- 前記用量は、2mgよりも少ない量である、請求項9に記載のシステム。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261740407P | 2012-12-20 | 2012-12-20 | |
US61/740,407 | 2012-12-20 | ||
US13/791,734 | 2013-03-08 | ||
US13/791,734 US9757395B2 (en) | 2012-12-20 | 2013-03-08 | Dry powder inhaler and methods of use |
PCT/US2013/032597 WO2014098945A1 (en) | 2012-12-20 | 2013-03-15 | Dry powder inhaler and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016504109A true JP2016504109A (ja) | 2016-02-12 |
JP6416779B2 JP6416779B2 (ja) | 2018-10-31 |
Family
ID=50973229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015549353A Active JP6416779B2 (ja) | 2012-12-20 | 2013-03-15 | 乾燥粉末吸入器および使用方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9757395B2 (ja) |
EP (3) | EP3613421B1 (ja) |
JP (1) | JP6416779B2 (ja) |
CN (1) | CN105007731A (ja) |
AU (1) | AU2016213728B2 (ja) |
CA (2) | CA3033296A1 (ja) |
DK (2) | DK2934134T3 (ja) |
ES (2) | ES2759319T3 (ja) |
FI (1) | FI3613421T3 (ja) |
HU (1) | HUE062264T2 (ja) |
MX (3) | MX2015007912A (ja) |
PL (2) | PL2934134T3 (ja) |
PT (2) | PT3613421T (ja) |
WO (1) | WO2014098945A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
JP2016518388A (ja) * | 2013-04-30 | 2016-06-23 | オティトピック インク. | 乾燥粉末配合および使用方法 |
WO2015127315A1 (en) | 2014-02-20 | 2015-08-27 | Otitopic Inc. | Dry powder formulations for inhalation |
PL3179986T3 (pl) * | 2014-07-31 | 2023-06-26 | Vectura Inc. | Suche formulacje w proszku do inhalacji |
WO2017210658A1 (en) | 2016-06-03 | 2017-12-07 | Otitopic Inc. | Dry powder formulations for inhalation |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
US10195147B1 (en) | 2017-09-22 | 2019-02-05 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
US11759397B2 (en) | 2020-10-07 | 2023-09-19 | S&SX-ray Products, Inc. | Medication dispensing arrangement without scanning |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885287A (en) * | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US20020025917A1 (en) * | 2000-08-28 | 2002-02-28 | Edward Pappalardo | Compartmentalized device to enable a process of liquefying and administering aspirin as a first aid to heart attack victims |
JP2002255814A (ja) * | 2000-12-25 | 2002-09-11 | Sankyo Co Ltd | アスピリンを含有する医薬組成物 |
JP2003525081A (ja) * | 2000-02-28 | 2003-08-26 | ヴェクチュラ リミテッド | 経口薬物の送達における改良、またはそれに関する改良 |
EP1350511A1 (en) * | 2000-12-25 | 2003-10-08 | Sankyo Company, Limited | Medicinal compositions containing aspirin |
JP2004509141A (ja) * | 2000-09-19 | 2004-03-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 中枢神経系の障害の処置における肺送達 |
US20070021382A1 (en) * | 2004-05-05 | 2007-01-25 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US7201929B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
GB2434754A (en) * | 2006-02-01 | 2007-08-08 | Trumeter Company Ltd | Inhaler with counter |
JP2009537199A (ja) * | 2006-05-16 | 2009-10-29 | ホビオン インター アーゲー | 簡易吸入器 |
US20100258118A1 (en) * | 2006-11-03 | 2010-10-14 | Vectura Limited | Inhaler devices and bespoke pharmaceutical compositions |
US20120291780A1 (en) * | 2010-12-07 | 2012-11-22 | Respira Therapeutics, Inc. | Bead-containing dry powder inhaler |
Family Cites Families (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2224175B1 (ja) | 1973-04-04 | 1978-04-14 | Isf Spa | |
BR8007911A (pt) | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
ATE179605T1 (de) | 1991-02-09 | 1999-05-15 | B S D Bio Science Dev Snc Di O | Antireaktive antiasthmatische wirkung von acetylsalicylsäure durch inhalation |
EP0499142A3 (en) | 1991-02-09 | 1993-05-05 | Hoechst Aktiengesellschaft | Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs |
US5256538A (en) | 1991-03-08 | 1993-10-26 | Board Of Regents, The University Of Texas System | Detection of early platelet activation and prediagnosis of thrombotic events |
US5327883A (en) | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
US6098620A (en) * | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US20070117862A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
PT101450B (pt) | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | Novo dispositivo para inalacao |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
AU706195B2 (en) | 1995-04-14 | 1999-06-10 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
US6209538B1 (en) | 1995-08-02 | 2001-04-03 | Robert A. Casper | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
AU766703B2 (en) | 1998-11-12 | 2003-10-23 | Frank G Pilkiewicz | An inhalation system |
JP3739955B2 (ja) | 1999-01-11 | 2006-01-25 | 株式会社日立製作所 | 吸入式投薬器 |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
DE60012347T2 (de) | 1999-10-12 | 2005-07-28 | Shl Medical Ab | Inhalator |
US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
US6998137B2 (en) | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
GB0010709D0 (en) | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
KR100527649B1 (ko) | 2000-06-12 | 2005-11-09 | 데이진 가부시키가이샤 | 분말약제 다회투여기 |
EP1177805A1 (en) | 2000-07-31 | 2002-02-06 | Maryland Financial Inc. | Powder inhaler |
FR2812545B1 (fr) | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
JP2004515467A (ja) | 2000-08-07 | 2004-05-27 | ネクター セラピューティックス | 吸入可能な、噴霧乾燥した、最少の凝集物を有する4−ヘリックスバンドルタンパク質粉末 |
FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
JP2004516304A (ja) | 2000-12-22 | 2004-06-03 | アスペン・エアロジエルズ・インコーポレーテツド | エーロゲル粉末含有治療剤 |
DE60101451T2 (de) | 2001-03-05 | 2004-10-21 | Pera Ivo E | Inhaliergerät zur Verteilung von in einer Kapsel enthaltenen Medikamenten in Pulverform durch die Atemwege |
US20060293217A1 (en) | 2001-03-19 | 2006-12-28 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
US6455028B1 (en) | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
US20040049022A1 (en) | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
GB0129270D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
GB0129397D0 (en) | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
ITMI20020078A1 (it) | 2002-01-16 | 2003-07-16 | Fabrizio Niccolai | Dispositivo utilizzabile nel tratamento di affezzioni delle vie respiratorie |
US20030232019A1 (en) | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
SE524990C2 (sv) | 2002-04-12 | 2004-11-09 | Microdrug Ag | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
US7405207B2 (en) | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
US20040092470A1 (en) | 2002-06-18 | 2004-05-13 | Leonard Sherry A. | Dry powder oligonucleotide formualtion, preparation and its uses |
WO2004030659A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
GB0226105D0 (en) | 2002-11-08 | 2002-12-18 | St Georges S Entpr Ltd | Pain relief agents |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
SE0203687D0 (sv) | 2002-12-13 | 2002-12-13 | Ian Harwigsson Med Adagit Fa | Pharmaceutical Porous Particles |
US20040206350A1 (en) | 2002-12-19 | 2004-10-21 | Nektar Therapeutics | Aerosolization apparatus with non-circular aerosolization chamber |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
US7878193B2 (en) | 2003-01-14 | 2011-02-01 | Boehringer Ingelheim International Gmbh | Capsule for taking an active substance which can be inhaled |
PT1610850E (pt) | 2003-04-09 | 2012-06-15 | Novartis Ag | Dispositivo para gerar um aerossol com protecção da entrada de ar |
EP1615689B1 (en) | 2003-04-09 | 2016-02-03 | Novartis AG | Aerosolization apparatus with capsule puncture alignment guide |
AU2004229567A1 (en) | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
GB0312419D0 (en) | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
AU2004249166B2 (en) | 2003-06-13 | 2008-10-09 | Alkermes, Inc. | Low dose pharmaceutical powders for inhalation |
SE527069C2 (sv) | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
WO2005035088A2 (en) | 2003-07-18 | 2005-04-21 | Baxter International, Inc. | Method for preparing small spherical by controlled phase separation |
JP2007502815A (ja) | 2003-08-20 | 2007-02-15 | イーライ リリー アンド カンパニー | Ppar調節因子 |
RU2006108864A (ru) | 2003-08-22 | 2007-09-27 | Берингер Ингельхайм Фармасьютиклз, Инк. (Us) | Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии |
US20050249697A1 (en) | 2003-09-24 | 2005-11-10 | Uhrich Kathryn E | Compositions and methods for the inhibition of bone growth and resorption |
GB2407040B (en) | 2003-10-15 | 2007-09-19 | Sheikh Arshad Saeed | Anti-platelet aggregation compositions |
WO2005040163A1 (en) | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
WO2005041886A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Methods for generating or increasing revenues related to pain inhibitor commerce |
US20070232575A1 (en) | 2004-02-05 | 2007-10-04 | Baulieu Etienne E | Treatment of Pulmonary Artery Hypertension with Dhea, Dheas, Dhea Analogs, or Dhea Derivatives |
US20050187268A1 (en) | 2004-02-23 | 2005-08-25 | Prolexys Pharmaceuticals Inc. | Non-peptidyl agents with pHSP20-like activity, and uses thereof |
KR101781166B1 (ko) | 2004-04-23 | 2017-09-22 | 사이덱스 파마슈티칼스, 인크. | 술포알킬 에테르 시클로덱스트린 함유 분말의 제조 방법 및 그 분말 |
AU2005238291A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
US7189750B2 (en) | 2004-05-05 | 2007-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof |
MXPA06012980A (es) | 2004-05-10 | 2007-06-12 | Nastech Pharm Co | Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. |
US7556035B2 (en) | 2004-05-28 | 2009-07-07 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
WO2006017354A1 (en) | 2004-07-13 | 2006-02-16 | Pharmacofore, Inc. | Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain |
JP2008509143A (ja) | 2004-08-04 | 2008-03-27 | シェーリング コーポレイション | 気道疾患の処置のためのプレコナリルを含む薬学的処方物 |
JP4948418B2 (ja) | 2004-11-02 | 2012-06-06 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Nkt細胞を抑制するための方法 |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
ITMI20050417A1 (it) | 2005-03-15 | 2006-09-16 | Medestea Res & Production S R L | Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
AU2006272483A1 (en) | 2005-07-27 | 2007-02-01 | Marina Biotech, Inc. | Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
WO2007070851A2 (en) | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
JP2009519975A (ja) | 2005-12-16 | 2009-05-21 | ユニバーシティ・オブ・カンザス | 治療薬を送達するナノクラスター |
WO2007072503A2 (en) | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
CA2932997C (en) | 2006-01-24 | 2019-07-30 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
US7806117B2 (en) | 2006-06-07 | 2010-10-05 | Shin Nippon Biomedical Laboratories, Ltd. | Peroral powder delivery device |
WO2008001132A1 (en) | 2006-06-27 | 2008-01-03 | Brintech International Limited | Inhaler |
JP2010500360A (ja) | 2006-08-10 | 2010-01-07 | アルボア コーポレーション | 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法 |
GB0617171D0 (en) | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
NL1033047C2 (nl) | 2006-12-13 | 2008-06-16 | Pharmachemie Bv | Capsule, gevuld met een medicijn, in het bijzonder een inhaleerbaar medicijn. |
GB0625303D0 (en) | 2006-12-19 | 2007-01-24 | Jagotec Ag | Improvements in and relating to metered dose inhalers |
GB0700839D0 (en) | 2007-01-17 | 2007-02-21 | Braithwaite Philip | Device |
EP1964564A1 (en) | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
CA2687720A1 (en) | 2007-06-13 | 2008-12-24 | Amgen Inc. | Il-17 heteromeric receptor complex |
US20090110679A1 (en) | 2007-07-13 | 2009-04-30 | Luk-Chiu Li | Methods and compositions for pulmonary administration of a TNFa inhibitor |
CA2692892A1 (en) | 2007-07-24 | 2009-01-29 | Michael Malakhov | Technology for the preparation of microparticles |
US9358242B2 (en) | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
WO2009075794A1 (en) | 2007-12-05 | 2009-06-18 | Nektar Therapeutics | Receptacle for an aerosolizable pharmaceutical formulation |
JP5767812B2 (ja) | 2007-12-06 | 2015-08-19 | バーグ リミテッド ライアビリティ カンパニー | 生物学的利用率が向上した吸入可能な組成物 |
WO2009086470A2 (en) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
DE102008004386A1 (de) | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
RU2534527C2 (ru) | 2008-01-15 | 2014-11-27 | Юниверсите Де Страсбур | Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов |
EP2250200A2 (en) | 2008-02-21 | 2010-11-17 | Amgen Inc. | Il-17ra-il-17rb antagonists and uses thereof |
GB0803369D0 (en) | 2008-02-25 | 2008-04-02 | Helperby Therapeutics Ltd | Biological materials and uses thereof |
JP2011516485A (ja) | 2008-04-04 | 2011-05-26 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Itpkb阻害剤としての化合物および組成物 |
WO2009128933A1 (en) | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders |
CN102056927B (zh) | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
KR101933816B1 (ko) | 2008-06-13 | 2019-03-29 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
WO2010009028A1 (en) | 2008-07-15 | 2010-01-21 | Schering Corporation | Intranasal compositions comprising a decongestant and a corticosteroid |
JP5936353B2 (ja) | 2008-07-18 | 2016-06-22 | プロソニックス リミテッドProsonix Limited | フルチカゾン粒子の結晶化度を改善する方法 |
WO2010011329A2 (en) | 2008-07-23 | 2010-01-28 | Map Pharmaceuticals, Inc. | The delivery of powdered drug via inhalation |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
RU2519193C2 (ru) | 2008-09-12 | 2014-06-10 | Критикал Фармасьютикалс Лимитед | Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу |
PE20120647A1 (es) | 2009-03-13 | 2012-05-31 | Nucitec Sa De Cv | Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular |
CA2754691C (en) | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
WO2010117951A1 (en) | 2009-04-06 | 2010-10-14 | The Regents Of The University Of California | Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing |
CN104817561B (zh) | 2009-04-20 | 2017-06-13 | 奥斯拜客斯制药有限公司 | Janus激酶3的哌啶抑制剂 |
GB0908129D0 (en) | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
US9101539B2 (en) | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
CA2762216C (en) | 2009-05-18 | 2017-07-11 | 3M Innovative Properties Company | Dry powder inhalers |
WO2010135253A2 (en) | 2009-05-18 | 2010-11-25 | 3M Innovative Properties Company | Dry powder inhaler dose counters |
JP2012528844A (ja) | 2009-06-01 | 2012-11-15 | バイオコピア リミテッド | 好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用 |
GB201111485D0 (en) | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
GB0917054D0 (en) | 2009-09-29 | 2009-11-11 | Cytoguide As | Agents, uses and methods |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
GB0918431D0 (en) | 2009-10-21 | 2009-12-09 | Prosonix Ltd | Process for improving crystallinity |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
NZ603045A (en) | 2010-04-07 | 2014-11-28 | Abbvie Inc | Tnf-alpha binding proteins |
CN103200938B (zh) | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
US8883844B2 (en) | 2010-09-24 | 2014-11-11 | Nitrogenix Inc. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions |
WO2012061902A1 (en) | 2010-11-12 | 2012-05-18 | Monash University | Micronised spray-dried particles comprising polymyxin |
CN102058886A (zh) | 2010-12-20 | 2011-05-18 | 云南白药集团无锡药业有限公司 | 医用粉雾剂及其应用 |
WO2012107364A1 (en) | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
GB201102237D0 (en) | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
CA2832910C (en) | 2011-04-12 | 2019-07-02 | Cynthia Lander | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CA2839270C (en) | 2011-06-17 | 2018-09-18 | Berg Llc | Inhalable liposomal pharmaceutical compositions |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
WO2013034910A1 (en) | 2011-09-06 | 2013-03-14 | Verona Pharma Plc | Inhalable compositions |
BR112014014594B1 (pt) | 2011-12-16 | 2021-02-17 | Indosys Limited | dispositivo de liberação de medicamento seco em pó |
EP2809686A4 (en) | 2012-01-31 | 2015-11-25 | Cerulean Pharma Inc | POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION |
NZ629438A (en) | 2012-02-28 | 2016-10-28 | Iceutica Holdings Inc | Inhalable pharmaceutical compositions |
CA2865972C (en) | 2012-02-29 | 2022-01-04 | Pulmatrix, Inc. | Inhalable dry powders |
WO2013148460A1 (en) | 2012-03-26 | 2013-10-03 | Swenson Rolf E | Novel sphingosine 1-phosphate receptor antagonists |
GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
CN104661647A (zh) | 2012-05-03 | 2015-05-27 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
WO2013176622A1 (en) | 2012-05-21 | 2013-11-28 | Agency For Science, Technology And Research (A*Star) | A dry powder formulation |
US9993439B2 (en) | 2012-06-20 | 2018-06-12 | University Of Waterloo | Mucoadhesive nanoparticle delivery system |
WO2014048065A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
US20150224129A1 (en) | 2012-10-03 | 2015-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
WO2014074422A1 (en) | 2012-11-07 | 2014-05-15 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
EA033113B1 (ru) | 2013-01-28 | 2019-08-30 | Инкозен Терапьютикс Пвт. Лтд. | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
GB201305813D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | Compositions and methods |
JP2016518388A (ja) | 2013-04-30 | 2016-06-23 | オティトピック インク. | 乾燥粉末配合および使用方法 |
JP2016534976A (ja) | 2013-05-23 | 2016-11-10 | アズセラピーズ インコーポレイテッド | クロモリンを送達する方法 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
CA2926793C (en) | 2013-10-11 | 2022-11-22 | Lawrence S. ZISMAN | Spray-dry formulations for treating pulmonary arterial hypertension |
WO2015127315A1 (en) | 2014-02-20 | 2015-08-27 | Otitopic Inc. | Dry powder formulations for inhalation |
EP4008726A1 (en) | 2014-02-20 | 2022-06-08 | Allergan, Inc. | Complement component c5 antibodies |
RU2018135371A (ru) | 2014-02-27 | 2018-12-10 | Аллерган, Инк. | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb |
CN106715443A (zh) | 2014-03-26 | 2017-05-24 | 坎格特生物技术制药有限责任公司 | Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途 |
WO2015153838A1 (en) | 2014-04-02 | 2015-10-08 | Rogne Bioscience Inc. | Methods and compositions for treating inflammatory disorders |
EP3129013A1 (en) | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
-
2013
- 2013-03-08 US US13/791,734 patent/US9757395B2/en active Active
- 2013-03-15 MX MX2015007912A patent/MX2015007912A/es active IP Right Grant
- 2013-03-15 JP JP2015549353A patent/JP6416779B2/ja active Active
- 2013-03-15 FI FIEP19194560.9T patent/FI3613421T3/fi active
- 2013-03-15 DK DK13864747T patent/DK2934134T3/da active
- 2013-03-15 CA CA3033296A patent/CA3033296A1/en active Pending
- 2013-03-15 ES ES13864747T patent/ES2759319T3/es active Active
- 2013-03-15 EP EP19194560.9A patent/EP3613421B1/en active Active
- 2013-03-15 PT PT191945609T patent/PT3613421T/pt unknown
- 2013-03-15 PL PL13864747T patent/PL2934134T3/pl unknown
- 2013-03-15 DK DK19194560.9T patent/DK3613421T3/da active
- 2013-03-15 CN CN201380073320.3A patent/CN105007731A/zh active Pending
- 2013-03-15 MX MX2020003436A patent/MX2020003436A/es unknown
- 2013-03-15 PL PL19194560.9T patent/PL3613421T3/pl unknown
- 2013-03-15 PT PT138647474T patent/PT2934134T/pt unknown
- 2013-03-15 HU HUE19194560A patent/HUE062264T2/hu unknown
- 2013-03-15 EP EP13864747.4A patent/EP2934134B1/en active Active
- 2013-03-15 EP EP23164415.4A patent/EP4233874A3/en active Pending
- 2013-03-15 WO PCT/US2013/032597 patent/WO2014098945A1/en active Application Filing
- 2013-03-15 CA CA2895398A patent/CA2895398C/en active Active
- 2013-03-15 ES ES19194560T patent/ES2946261T3/es active Active
-
2015
- 2015-06-18 MX MX2022009231A patent/MX2022009231A/es unknown
-
2016
- 2016-08-09 AU AU2016213728A patent/AU2016213728B2/en active Active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4885287A (en) * | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
JPH04500070A (ja) * | 1988-08-09 | 1992-01-09 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | アスピリンの新規投与方法およびアスピリンを含有する新規剤形 |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
JP2003525081A (ja) * | 2000-02-28 | 2003-08-26 | ヴェクチュラ リミテッド | 経口薬物の送達における改良、またはそれに関する改良 |
US20020025917A1 (en) * | 2000-08-28 | 2002-02-28 | Edward Pappalardo | Compartmentalized device to enable a process of liquefying and administering aspirin as a first aid to heart attack victims |
JP2004509141A (ja) * | 2000-09-19 | 2004-03-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 中枢神経系の障害の処置における肺送達 |
EP1350511A1 (en) * | 2000-12-25 | 2003-10-08 | Sankyo Company, Limited | Medicinal compositions containing aspirin |
JP2002255814A (ja) * | 2000-12-25 | 2002-09-11 | Sankyo Co Ltd | アスピリンを含有する医薬組成物 |
US20070021382A1 (en) * | 2004-05-05 | 2007-01-25 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US7201929B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
GB2434754A (en) * | 2006-02-01 | 2007-08-08 | Trumeter Company Ltd | Inhaler with counter |
JP2009537199A (ja) * | 2006-05-16 | 2009-10-29 | ホビオン インター アーゲー | 簡易吸入器 |
US20100258118A1 (en) * | 2006-11-03 | 2010-10-14 | Vectura Limited | Inhaler devices and bespoke pharmaceutical compositions |
US20120291780A1 (en) * | 2010-12-07 | 2012-11-22 | Respira Therapeutics, Inc. | Bead-containing dry powder inhaler |
Also Published As
Publication number | Publication date |
---|---|
ES2759319T3 (es) | 2020-05-08 |
EP2934134B1 (en) | 2019-09-25 |
US20140174437A1 (en) | 2014-06-26 |
AU2016213728A1 (en) | 2016-08-25 |
EP2934134A4 (en) | 2016-08-17 |
PT2934134T (pt) | 2019-12-03 |
EP4233874A2 (en) | 2023-08-30 |
DK3613421T3 (da) | 2023-06-12 |
HUE062264T2 (hu) | 2023-10-28 |
DK2934134T3 (da) | 2019-11-25 |
CA3033296A1 (en) | 2014-06-26 |
MX2015007912A (es) | 2016-03-03 |
EP2934134A1 (en) | 2015-10-28 |
MX2020003436A (es) | 2022-07-27 |
PL2934134T3 (pl) | 2020-04-30 |
ES2946261T3 (es) | 2023-07-14 |
CA2895398C (en) | 2019-02-12 |
WO2014098945A1 (en) | 2014-06-26 |
JP6416779B2 (ja) | 2018-10-31 |
CN105007731A (zh) | 2015-10-28 |
AU2013205497A1 (en) | 2014-07-10 |
FI3613421T3 (fi) | 2023-06-07 |
CA2895398A1 (en) | 2014-06-26 |
PL3613421T3 (pl) | 2023-07-31 |
US9757395B2 (en) | 2017-09-12 |
MX2022009231A (es) | 2022-09-07 |
EP3613421A1 (en) | 2020-02-26 |
EP3613421B1 (en) | 2023-05-03 |
EP4233874A3 (en) | 2023-11-01 |
PT3613421T (pt) | 2023-06-19 |
AU2016213728B2 (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6416779B2 (ja) | 乾燥粉末吸入器および使用方法 | |
US11819569B2 (en) | Treating inflammation with inhaled aspirin | |
Ye et al. | The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders? | |
US20190224427A1 (en) | Dry powder inhaler and methods of use | |
EP1177793A1 (fr) | Aérosol médicamenteux inhalable dans le traitement ou la prévention de la douleur | |
US20160022705A1 (en) | Dry powder formulations for inhalation | |
Sheikh et al. | Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment? | |
JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
KR20090110782A (ko) | 폐 내부 영역에 대한 흡입 투여 또는 점적 투여 대상 활성물질의 담체로서 부분 불소치환 알칸의 사용 | |
Hingankar et al. | Lung Delivery for Pulmonary Tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170419 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170719 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180622 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181004 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6416779 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |